These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Should moral objections to synthetic biology affect public policy? Kaebnick GE Nat Biotechnol; 2009 Dec; 27(12):1106-8. PubMed ID: 20010586 [No Abstract] [Full Text] [Related]
24. Could bank loans solve Europe's biotech financing slump? Mitchell P Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276 [No Abstract] [Full Text] [Related]
25. Lessons for the nascent regenerative medicine industry from the biotech sector. Mason C; Dunnill P Regen Med; 2007 Sep; 2(5):753-6. PubMed ID: 17907927 [No Abstract] [Full Text] [Related]
26. White biotechnology: ready to partner and invest in. Kircher M Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821 [TBL] [Abstract][Full Text] [Related]
27. How to turn industrial biotechnology into reality. Kircher M N Biotechnol; 2012 Jan; 29(2):243-7. PubMed ID: 22100431 [TBL] [Abstract][Full Text] [Related]
28. Japanese giants renew interest in industrial biotech. Sipp D Nat Biotechnol; 2005 Mar; 23(3):275-6. PubMed ID: 15765071 [No Abstract] [Full Text] [Related]
29. Biotechnological studies in the Far-Eastern Region of Russia. Stonik VA; Mikhailov VV; Bulgakov VP; Zhuravlev YN Biotechnol J; 2007 Jul; 2(7):818-25. PubMed ID: 17582826 [TBL] [Abstract][Full Text] [Related]
32. Korean biotechs seize opportunity to list on public markets. Louët S Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042 [No Abstract] [Full Text] [Related]
33. Hydrocarbons and renewable energy. Ringpfeil M Nat Biotechnol; 2004 Sep; 22(9):1077. PubMed ID: 15340466 [No Abstract] [Full Text] [Related]
37. Enthusiasm cools in Q2. Lawrence S Nat Biotechnol; 2005 Aug; 23(8):914. PubMed ID: 16082352 [No Abstract] [Full Text] [Related]
38. Public biotech 2006 - the numbers. Lähteenmäki R; Lawrence S Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294 [No Abstract] [Full Text] [Related]
39. The way to a powerful business plan. Schneider JE Drug Discov Today; 2002 Mar; 7(6):342-5. PubMed ID: 11893539 [No Abstract] [Full Text] [Related]
40. Sir Chris Evans divulges his experiences as an entrepreneur. Interview by Rebecca N. Lawrence. Evans C Drug Discov Today; 2002 Apr; 7(7):399-402. PubMed ID: 11916565 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]